Chronic paraplegia-induced muscle atrophy downregulates the mTOR/S6K1 signaling pathway

Hans C. Dreyer, Erin L. Glynn, Heidi L. Lujan, Christopher Fry, Stephen E. DiCarlo, Blake Rasmussen

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Ribosomal S6 kinase 1 (S6K1) is a downstream component of the mammalian target of rapamycin (mTOR) signaling pathway and plays a regulatory role in translation initiation, protein synthesis, and muscle hypertrophy. AMP-activated protein kinase (AMPK) is a cellular energy sensor, a negative regulator of mTOR, and an inhibitor of protein synthesis. The purpose of this study was to determine whether the hypertrophy/cell growth-associated mTOR pathway was downregulated during muscle atrophy associated with chronic paraplegia. Soleus muscle was collected from male Sprague-Dawley rats 10 wk following complete T4-T5 spinal cord transection (paraplegic) and from sham-operated (control) rats. We utilized immunoprecipitation and Western blotting techniques to measure upstream [AMPK, Akt/protein kinase B (PKB)] and downstream components of the mTOR signaling pathway [mTOR, S6K1, SKAR, 4E-binding protein 1 (4E-BP1), and eukaryotic initiation factor (eIF) 4G and 2α]. Paraplegia was associated with significant soleus muscle atrophy (174 ± 8 vs. 240 ± 13 mg; P < 0.05). There was a reduction in phosphorylation of mTOR, S6K1, and eIF4G (P < 0.05) with no change in Akt/PKB or 4E-BP1 (P > 0.05). Total protein abundance of mTOR, S6K1, eIF2α, and Akt/PKB was decreased, and increased for SKAR (P < 0.05), whereas 4E-BP1 and eIF4G did not change (P > 0.05). S6K1 activity was significantly reduced in the paraplegic group (P < 0.05); however, AMPKα2 activity was not altered (3.5 ± 0.4 vs. 3.7 ± 0.5 pmol·mg -1·min-1, control vs. paraplegic rats). We conclude that paraplegia-induced muscle atrophy in rats is associated with a general downregulation of the mTOR signaling pathway. Therefore, in addition to upregulation of atrophy signaling during muscle wasting, downregulation of muscle cell growth/hypertrophy-associated signaling appears to be an important component of long-term muscle loss.

Original languageEnglish (US)
Pages (from-to)27-33
Number of pages7
JournalJournal of Applied Physiology
Volume104
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Ribosomal Protein S6 Kinases
Muscular Atrophy
Paraplegia
Sirolimus
Down-Regulation
Hypertrophy
Proto-Oncogene Proteins c-akt
AMP-Activated Protein Kinases
Muscles
Eukaryotic Initiation Factor-4G
Skeletal Muscle
Translational Peptide Chain Initiation
Eukaryotic Initiation Factor-2
TOR Serine-Threonine Kinases
Growth
Spinal Cord Injuries
Immunoprecipitation
Muscle Cells
Atrophy
Sprague Dawley Rats

Keywords

  • Akt
  • AMP-activated protein kinase
  • Muscle wasting
  • Rehabilitation
  • Spinal cord injury

ASJC Scopus subject areas

  • Physiology
  • Endocrinology
  • Orthopedics and Sports Medicine
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Chronic paraplegia-induced muscle atrophy downregulates the mTOR/S6K1 signaling pathway. / Dreyer, Hans C.; Glynn, Erin L.; Lujan, Heidi L.; Fry, Christopher; DiCarlo, Stephen E.; Rasmussen, Blake.

In: Journal of Applied Physiology, Vol. 104, No. 1, 01.2008, p. 27-33.

Research output: Contribution to journalArticle

Dreyer, Hans C. ; Glynn, Erin L. ; Lujan, Heidi L. ; Fry, Christopher ; DiCarlo, Stephen E. ; Rasmussen, Blake. / Chronic paraplegia-induced muscle atrophy downregulates the mTOR/S6K1 signaling pathway. In: Journal of Applied Physiology. 2008 ; Vol. 104, No. 1. pp. 27-33.
@article{0f6c7c7cc8d44e128864d341428221c5,
title = "Chronic paraplegia-induced muscle atrophy downregulates the mTOR/S6K1 signaling pathway",
abstract = "Ribosomal S6 kinase 1 (S6K1) is a downstream component of the mammalian target of rapamycin (mTOR) signaling pathway and plays a regulatory role in translation initiation, protein synthesis, and muscle hypertrophy. AMP-activated protein kinase (AMPK) is a cellular energy sensor, a negative regulator of mTOR, and an inhibitor of protein synthesis. The purpose of this study was to determine whether the hypertrophy/cell growth-associated mTOR pathway was downregulated during muscle atrophy associated with chronic paraplegia. Soleus muscle was collected from male Sprague-Dawley rats 10 wk following complete T4-T5 spinal cord transection (paraplegic) and from sham-operated (control) rats. We utilized immunoprecipitation and Western blotting techniques to measure upstream [AMPK, Akt/protein kinase B (PKB)] and downstream components of the mTOR signaling pathway [mTOR, S6K1, SKAR, 4E-binding protein 1 (4E-BP1), and eukaryotic initiation factor (eIF) 4G and 2α]. Paraplegia was associated with significant soleus muscle atrophy (174 ± 8 vs. 240 ± 13 mg; P < 0.05). There was a reduction in phosphorylation of mTOR, S6K1, and eIF4G (P < 0.05) with no change in Akt/PKB or 4E-BP1 (P > 0.05). Total protein abundance of mTOR, S6K1, eIF2α, and Akt/PKB was decreased, and increased for SKAR (P < 0.05), whereas 4E-BP1 and eIF4G did not change (P > 0.05). S6K1 activity was significantly reduced in the paraplegic group (P < 0.05); however, AMPKα2 activity was not altered (3.5 ± 0.4 vs. 3.7 ± 0.5 pmol·mg -1·min-1, control vs. paraplegic rats). We conclude that paraplegia-induced muscle atrophy in rats is associated with a general downregulation of the mTOR signaling pathway. Therefore, in addition to upregulation of atrophy signaling during muscle wasting, downregulation of muscle cell growth/hypertrophy-associated signaling appears to be an important component of long-term muscle loss.",
keywords = "Akt, AMP-activated protein kinase, Muscle wasting, Rehabilitation, Spinal cord injury",
author = "Dreyer, {Hans C.} and Glynn, {Erin L.} and Lujan, {Heidi L.} and Christopher Fry and DiCarlo, {Stephen E.} and Blake Rasmussen",
year = "2008",
month = "1",
doi = "10.1152/japplphysiol.00736.2007",
language = "English (US)",
volume = "104",
pages = "27--33",
journal = "Journal of Applied Physiology",
issn = "8750-7587",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - Chronic paraplegia-induced muscle atrophy downregulates the mTOR/S6K1 signaling pathway

AU - Dreyer, Hans C.

AU - Glynn, Erin L.

AU - Lujan, Heidi L.

AU - Fry, Christopher

AU - DiCarlo, Stephen E.

AU - Rasmussen, Blake

PY - 2008/1

Y1 - 2008/1

N2 - Ribosomal S6 kinase 1 (S6K1) is a downstream component of the mammalian target of rapamycin (mTOR) signaling pathway and plays a regulatory role in translation initiation, protein synthesis, and muscle hypertrophy. AMP-activated protein kinase (AMPK) is a cellular energy sensor, a negative regulator of mTOR, and an inhibitor of protein synthesis. The purpose of this study was to determine whether the hypertrophy/cell growth-associated mTOR pathway was downregulated during muscle atrophy associated with chronic paraplegia. Soleus muscle was collected from male Sprague-Dawley rats 10 wk following complete T4-T5 spinal cord transection (paraplegic) and from sham-operated (control) rats. We utilized immunoprecipitation and Western blotting techniques to measure upstream [AMPK, Akt/protein kinase B (PKB)] and downstream components of the mTOR signaling pathway [mTOR, S6K1, SKAR, 4E-binding protein 1 (4E-BP1), and eukaryotic initiation factor (eIF) 4G and 2α]. Paraplegia was associated with significant soleus muscle atrophy (174 ± 8 vs. 240 ± 13 mg; P < 0.05). There was a reduction in phosphorylation of mTOR, S6K1, and eIF4G (P < 0.05) with no change in Akt/PKB or 4E-BP1 (P > 0.05). Total protein abundance of mTOR, S6K1, eIF2α, and Akt/PKB was decreased, and increased for SKAR (P < 0.05), whereas 4E-BP1 and eIF4G did not change (P > 0.05). S6K1 activity was significantly reduced in the paraplegic group (P < 0.05); however, AMPKα2 activity was not altered (3.5 ± 0.4 vs. 3.7 ± 0.5 pmol·mg -1·min-1, control vs. paraplegic rats). We conclude that paraplegia-induced muscle atrophy in rats is associated with a general downregulation of the mTOR signaling pathway. Therefore, in addition to upregulation of atrophy signaling during muscle wasting, downregulation of muscle cell growth/hypertrophy-associated signaling appears to be an important component of long-term muscle loss.

AB - Ribosomal S6 kinase 1 (S6K1) is a downstream component of the mammalian target of rapamycin (mTOR) signaling pathway and plays a regulatory role in translation initiation, protein synthesis, and muscle hypertrophy. AMP-activated protein kinase (AMPK) is a cellular energy sensor, a negative regulator of mTOR, and an inhibitor of protein synthesis. The purpose of this study was to determine whether the hypertrophy/cell growth-associated mTOR pathway was downregulated during muscle atrophy associated with chronic paraplegia. Soleus muscle was collected from male Sprague-Dawley rats 10 wk following complete T4-T5 spinal cord transection (paraplegic) and from sham-operated (control) rats. We utilized immunoprecipitation and Western blotting techniques to measure upstream [AMPK, Akt/protein kinase B (PKB)] and downstream components of the mTOR signaling pathway [mTOR, S6K1, SKAR, 4E-binding protein 1 (4E-BP1), and eukaryotic initiation factor (eIF) 4G and 2α]. Paraplegia was associated with significant soleus muscle atrophy (174 ± 8 vs. 240 ± 13 mg; P < 0.05). There was a reduction in phosphorylation of mTOR, S6K1, and eIF4G (P < 0.05) with no change in Akt/PKB or 4E-BP1 (P > 0.05). Total protein abundance of mTOR, S6K1, eIF2α, and Akt/PKB was decreased, and increased for SKAR (P < 0.05), whereas 4E-BP1 and eIF4G did not change (P > 0.05). S6K1 activity was significantly reduced in the paraplegic group (P < 0.05); however, AMPKα2 activity was not altered (3.5 ± 0.4 vs. 3.7 ± 0.5 pmol·mg -1·min-1, control vs. paraplegic rats). We conclude that paraplegia-induced muscle atrophy in rats is associated with a general downregulation of the mTOR signaling pathway. Therefore, in addition to upregulation of atrophy signaling during muscle wasting, downregulation of muscle cell growth/hypertrophy-associated signaling appears to be an important component of long-term muscle loss.

KW - Akt

KW - AMP-activated protein kinase

KW - Muscle wasting

KW - Rehabilitation

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=38349038401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349038401&partnerID=8YFLogxK

U2 - 10.1152/japplphysiol.00736.2007

DO - 10.1152/japplphysiol.00736.2007

M3 - Article

C2 - 17885021

AN - SCOPUS:38349038401

VL - 104

SP - 27

EP - 33

JO - Journal of Applied Physiology

JF - Journal of Applied Physiology

SN - 8750-7587

IS - 1

ER -